In a patient with chronic kidney disease and pulmonary tuberculosis on anti‑tubercular therapy who presents with bilateral peripheral neuropathy (numbness and pain in hands and feet) and has already planned thyroid function tests, magnesium level, cervical spine MRI, vitamin B12 level, peripheral smear, and started gabapentin 300 mg nightly and duloxetine 20 mg daily, what additional investigations or management steps should be undertaken?

Management of Peripheral Neuropathy in CKD Patient on Anti-Tubercular Therapy

Immediately start pyridoxine (vitamin B6) 100 mg daily—this patient has chronic kidney disease and is at high risk for isoniazid-induced peripheral neuropathy, which should have been prophylactically administered from the start of ATT. 1

Critical Immediate Actions

1. Pyridoxine Supplementation - URGENT

• Start pyridoxine 100 mg daily immediately (not the standard 10 mg dose)
• CKD patients are specifically identified as high-risk for isoniazid-induced neuropathy requiring prophylaxis 1
• This should have been initiated at ATT start but must be added now
• Higher doses (up to 200 mg daily) may be needed in established neuropathy

2. Dose Verification for CKD

• Verify all ATT drug doses are adjusted for renal function
• Ethambutol and streptomycin require substantial dose reduction or avoidance in renal failure 1
• If these drugs must be used, serum drug concentrations should be monitored 1
• CKD patients have 4-5 times higher risk of ATT-associated adverse drug reactions 2

3. Complete the Planned Investigations

The provider's plan is appropriate but add:

• Serum pyridoxine level (if available)
• HIV testing (if not already done - HIV increases neuropathy risk) 1
• HbA1c or fasting glucose (diabetes assessment - another high-risk factor) 1
• Nutritional assessment including albumin (malnutrition increases risk) 1
• Drug levels of isoniazid/ethambutol if available in your setting 1

Medication Adjustments

4. Optimize Neuropathic Pain Management

Current regimen (gabapentin 300 mg nightly, duloxetine 20 mg daily) needs adjustment:

Gabapentin dosing in CKD:

• Must be dose-adjusted based on creatinine clearance 3
• For CrCl 30-59 mL/min: 200-300 mg twice daily maximum
• For CrCl 15-29 mL/min: 200-300 mg once daily maximum
• For CrCl <15 mL/min or hemodialysis: 100-300 mg once daily plus post-dialysis supplementation 3
• Current dosing of 300 mg nightly may be appropriate or excessive depending on actual renal function
• Maximum interval between doses should not exceed 12 hours 3

Duloxetine:

• 20 mg daily is appropriate starting dose
• Can titrate to 60 mg daily for optimal effect 4
• Monitor for increased A1C in diabetic patients 4

5. ATT Regimen Modification

If neuropathy worsens despite pyridoxine:

• Consider isoniazid-free regimen as provider suggested 1
• Alternative: Rifampicin + ethambutol + pyrazinamide + fluoroquinolone for 18 months 1
• Requires infectious disease/TB specialist consultation 1
• Document drug sensitivity testing results before modification

Monitor for other neurotoxic ATT drugs:

• Ethambutol can cause optic neuropathy (separate from peripheral neuropathy) 1
• Linezolid (if used in drug-resistant TB) causes peripheral neuropathy in 10-12 weeks 5
• Fluoroquinolones can contribute to neuropathy

Additional Management Steps

6. Neurological Monitoring

• Weekly assessment of neuropathy severity using standardized grading
• Document motor strength, sensory examination, reflexes, gait
• If Grade 3-4 neuropathy develops, ATT modification is mandatory 6
• Consider nerve conduction studies if diagnosis unclear or not improving 6, 7

7. Address Thyroid Function

• Interpret thyroid tests cautiously in CKD - abnormal results often reflect non-thyroidal illness rather than true hypothyroidism 8
• Repeat testing after volume optimization and at consistent point in dialysis cycle (if on dialysis) 8
• Low T3 is common in CKD and correlates with inflammation/malnutrition, not necessarily requiring treatment 8
• Only treat if persistent overt primary hypothyroidism confirmed on repeat testing 8

8. Nutritional Support

• Assess and correct malnutrition - major risk factor for neuropathy in TB patients 1, 9
• Consider B-complex supplementation beyond pyridoxine
• Protein-energy supplementation if indicated

Critical Pitfalls to Avoid

1. Do NOT delay pyridoxine - this is preventable neurotoxicity
2. Do NOT use standard gabapentin dosing - requires renal adjustment 3
3. Do NOT assume thyroid abnormalities require treatment - CKD causes non-thyroidal illness patterns 8
4. Do NOT continue full-dose ethambutol/streptomycin without dose adjustment in CKD 1
5. Do NOT attribute all neuropathy to isoniazid - ethambutol, linezolid, and TB itself can cause neuropathy 6, 5, 7

Prognosis and Follow-up

• Most ATT-induced neuropathy shows limited recovery even after drug cessation 6
• Improvement may take months to years after stopping offending agent 7
• Early intervention with pyridoxine and dose adjustment offers best chance for recovery
• Some patients develop permanent disability requiring long-term pain management 9

The single most important missing intervention is immediate pyridoxine supplementation at therapeutic doses (100 mg daily), which should have been started prophylactically given this patient's CKD status.